Athira Pharma (NASDAQ:LONA) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Athira Pharma (NASDAQ:LONA) in a research report report published on Thursday, Marketbeat.com reports. The firm issued an overweight rating on the stock.

Several other equities analysts also recently weighed in on LONA. Weiss Ratings initiated coverage on Athira Pharma in a research report on Wednesday, February 11th. They issued a “sell (d-)” rating for the company. Mizuho raised shares of Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 price objective for the company in a research note on Thursday, February 19th. Finally, Wall Street Zen upgraded shares of Athira Pharma to a “hold” rating in a report on Saturday, February 14th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $10.00.

Athira Pharma Stock Down 3.3%

NASDAQ:LONA opened at $5.62 on Thursday. Athira Pharma has a 52 week low of $2.20 and a 52 week high of $8.36.

Athira Pharma Company Profile

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.